Amanote Research
Register
Sign In
211. rAAV Mediated Modulation of miR-1 Influences the Progression of Hepatocellular Carcinoma in a Mouse Model of Alpha-1 Antitrypsin
Molecular Therapy
- United States
doi 10.1016/s1525-0016(16)34546-4
Full Text
Open PDF
Abstract
Available in
full text
Categories
Molecular Medicine
Molecular Biology
Pharmacology
Medicine
Genetics
Drug Discovery
Date
May 1, 2013
Authors
Unknown
Publisher
Elsevier BV
Related search
Alpha 1-Antitrypsin-Labor Und Alpha 1-Antitrypsin-Register
Pneumologie
Medicine
Pulmonary
Respiratory Medicine
Alpha 1 Antitrypsin Inhibits Dendritic Cell Activation and Attenuates Nephritis in a Mouse Model of Lupus
PLoS ONE
Multidisciplinary
Safety and Efficacy of Alpha-1-Antitrypsin Augmentation Therapy in the Treatment of Patients With Alpha-1-Antitrypsin Deficiency
Biologics: Targets and Therapy
Oncology
Immunology
Gastroenterology
Pharmacology
Rheumatology
Allergy
Alpha-1-Antitrypsin Deficiency
Alpha-1 Antitrypsin Deficiency
Journal of insurance medicine (New York, N.Y.)
Medicine
Alpha‐1‐Antitrypsin Deficiency
Modulation of miR-29 Expression by Alpha-Fetoprotein Is Linked to the Hepatocellular Carcinoma Epigenome
Hepatology
Medicine
Hepatology
Production of Glycosylated Physiologically "Normal" Human Alpha 1-Antitrypsin by Mouse Fibroblasts Modified by Insertion of a Human Alpha 1-Antitrypsin cDNA Using a Retroviral Vector.
Proceedings of the National Academy of Sciences of the United States of America
Multidisciplinary
Orphan Designation: Alpha-1 Antitrypsin (Inhalation Use), Treatment of Emphysema Secondary to Congenital Alpha-1-Antitrypsin Deficiency
Case Medical Research
